Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TriSalus Life Sciences, Inc. (TLSI)

TriSalus Receives FDA 510(k) Clearance for TriNav Advance Device

Neutral Impact 3 of 5 product/contract Written later

TriSalus Life Sciences said it received FDA 510(k) clearance for its TriNav Advance device, an addition to its Pressure-Enabled Drug Delivery portfolio. The company expects to begin commercialization with the clearance and plans a limited market release over the coming weeks.

Key points

  • FDA 510(k) clearance announced September 22, 2026 for TriNav Advance
  • Device can be used in telescoping configuration with a compatible microcatheter to reach smaller, distal vessels, or in high-flow configuration without one
  • Company intends to initiate a limited market release over the coming weeks

The filing

CompanyTriSalus Life Sciences, Inc. (TLSI)
Form8-K, current report
Filed with the SECSep 22, 2026, 4:14 PM ET
Accession number0001628280-26-063031

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.